| abstract |
The present invention provides, inter alia, novel, liposome-based formulations for enhanced ophthalmic drug delivery. Such ophthalmic drug formulations are useful for treating ocular inflammation stemming from, for example, iritis, conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, masquerade syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion, or blood-aqueous barrier disruption, and for treating post-operative ocular inflammation, resulting from, for example, photorefractive keratectomy, cataract removal surgery, intraocular lens implantation or radial keratotomy. |